AIIMS Delhi hosts workshop on ‘Emerging Technologies for Healthcare’
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Aarti Drugs has reported total income of Rs. 599.81 crores during the period ended September 30, 2024
Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024
Thyrocare Technologies has reported total income of Rs. 179.97 crores during the period ended September 30, 2024
Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Silica is a proven and highly effective anti-caking agent that has been used for decades
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
Subscribe To Our Newsletter & Stay Updated